WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 203187

CAS#: 1349796-36-6

Description: Voxtalisib, also known as XL-765 and SAR245409, is a PI3K/mTOR dual kinase inhibitor XL765 is an orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR dual kinase inhibitor XL765 inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cell populations.

Price and Availability


USD 750
USD 3250

USD 1250
USD 4950

USD 1950
USD 8450

Voxtalisib, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 203187
Name: Voxtalisib
CAS#: 1349796-36-6
Chemical Formula: C31H29N5O6S
Exact Mass: 599.1839
Molecular Weight: 599.662
Elemental Analysis: C, 62.09; H, 4.87; N, 11.68; O, 16.01; S, 5.35

Synonym: XL765, XL 765, XL-765, SAR245409, SAR245409, SAR 245409, Voxtalisib

IUPAC/Chemical Name: N-(4-(N-(3-((3,5-dimethoxyphenyl)amino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide


InChi Code: InChI=1S/C31H29N5O6S/c1-19-9-10-20(15-28(19)42-4)31(37)33-21-11-13-25(14-12-21)43(38,39)36-30-29(34-26-7-5-6-8-27(26)35-30)32-22-16-23(40-2)18-24(17-22)41-3/h5-18H,1-4H3,(H,32,34)(H,33,37)(H,35,36)


Technical Data

White solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug is formulated in DMSO.

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1.Annotating cancer variants and anti-cancer therapeutics in Reactome By Milacic, Marija; Haw, Robin; Rothfels, Karen; Wu, Guanming; Croft, David; Hermjakob, Henning; D'Eustachio, Peter; Stein, Lincoln From Cancers (2012), 4, 1180-1211.

2. P13K-Akt-mTOR signaling pathway and its inhibitors By Dan, Shingo; Yamori, Takao From Gan Bunshi Hyoteki Chiryo (2012), 10(2), 101-109.

3.Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors By Ghadimi, Markus P.; Lopez, Gonzalo; Torres, Keila E.; Belousov, Roman; Young, Eric D.; Liu, Jeffery; Brewer, Kari J.; Hoffman, Aviad; Lusby, Kristelle; Lazar, Alexander J.; et al From Molecular Cancer Therapeutics (2012), 11(8), 1758-1769.

4. mTOR kinase inhibitors as a treatment strategy in hematological malignancies By Grzybowska-Izydorczyk, Olga; Smolewski, Piotr From Future Medicinal Chemistry (2012), 4(4), 487-504.

5. Targeting the PI3K signaling pathway in cancer therapy By Bartholomeusz, Chandra; Gonzalez-Angulo, Ana Maria From Expert Opinion on Therapeutic Targets (2012), 16(1), 121-130.

6. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma By Mirzoeva, Olga K.; Hann, Byron; Hom, Yun K.; Debnath, Jayanta; Aftab, Dana; Shokat, Kevan; Korn, W. Michael From Journal of Molecular Medicine (Heidelberg, Germany) (2011), 89(9), 877-889.

7. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide By Prasad, Gautam; Sottero, Theo; Yang, Xiaodong; Mueller, Sabine; James, C. David; Weiss, William A.; Polley, Mei-Yin; Ozawa, Tomoko; Berger, Mitchel S.; Aftab, Dana T.; et al From Neuro-Oncology (Cary, NC, United States) (2011), 13(4), 384-392.

7. Docking Studies on Isoform-Specific Inhibition of Phosphoinositide-3-Kinases By Sabbah, Dima A.; Vennerstrom, Jonathan L.; Zhong, Haizhen From Journal of Chemical Information and Modeling (2010), 50(10), 1887-1898.

8. Inhibitors of phosphatidylinositol 3-kinases: the next wave of anti-cancer drugs? By Rewcastle, Gordon W.; Denny, William A. From Chemistry in New Zealand (2009), 73(1), 9-11.